Online inquiry

IVTScrip™ mRNA-Anti-ALB&IL6R, 20A11-9mer-ALB11(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ358MR)

This product GTTS-WQ358MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets ALB&IL6R gene. The antibody can be applied in Inflammatory conditions, Systemic lupus erythematosus (SLE) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000477.7; NM_002190.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 213; 3570
UniProt ID P02768; P08887
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ALB&IL6R, 20A11-9mer-ALB11(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ358MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8325MR IVTScrip™ mRNA-Anti-TFRC, HN-66000(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA HN-66000
GTTS-WQ9392MR IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA Interleukin 2
GTTS-WQ9687MR IVTScrip™ mRNA-Anti-KLRK1, JNJ-64304500(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA JNJ-64304500
GTTS-WQ684MR IVTScrip™ mRNA-Anti-IL17A&TNF, A-1230717(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA A-1230717
GTTS-WQ8296MR IVTScrip™ mRNA-Anti-GLP1R, HM-12525A(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA HM-12525A
GTTS-WQ13063MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, PEG-IFN-SA(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PEG-IFN-SA
GTTS-WQ12574MR IVTScrip™ mRNA-Anti-Felcat NGF, NV-02(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA NV-02
GTTS-WQ10619MR IVTScrip™ mRNA-Anti-MAPT, LY-3303560(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LY-3303560
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW